Ion Biotech Group and Ionic Alliance Group Sign a Collaboration Agreement

Grupo Ion Biotech and Ionic Alliance Group Create a Strategic Collaboration for Global Expansion

Grupo Ion Biotech, S.A.P.I. de C.V., the parent company of Ion Biotechnology México, has officially entered into a strategic collaboration with Ionic Alliance Group, Inc., a U.S.-based organization specializing in health technology integration and global commercialization platforms. This partnership signals a bold move to amplify the international presence and technological ecosystem surrounding Ion Biotech’s proprietary innovation—Ion Gel ZCM-25®, and its core platform, IBAL (Ion Biotechnology Aqueous Ligands).

The agreement represents not only a formal business alignment but also a shared vision for advancing topical antimicrobial therapies and redox-based immune support solutions globally. Together, these two organizations will leverage their complementary strengths in research, digital infrastructure, market access, and regulatory expertise to scale the impact of Ion Gel ZCM-25® and future IBAL-based medical innovations.

Purpose of the Collaboration

At the heart of this agreement is a strategic roadmap for internationalization, scientific knowledge-sharing, and ecosystem-building around IBAL technology.

The collaboration outlines several key initiatives:

• Data and Research Sharing: Both groups will jointly curate and disseminate clinical data, product research, and safety studies related to IBAL technology and its therapeutic outcomes.
• Cross-Border Licensing and Commercialization: Teams will collaborate on expanding product licensing and commercialization in Mexico, the U.S., and additional global markets.
• Resource and Advisor Integration: Access to regional advisors, licensees, vendors, and supply chains will be streamlined across both organizations.

This alliance allows for a smoother global rollout of Ion Gel ZCM-25®, particularly in regulated markets seeking innovative, safe, and evidence-based wound healing and infection control solutions.

About Ionic Alliance Group and the 2+ Cations® Community

Ionic Alliance Group, Inc. brings a robust digital and operational infrastructure to the partnership through its flagship platform, 2+ Cations®—a secure, cloud-based ecosystem designed to support healthcare professionals, researchers, distributors, and licensees.

This multilingual platform provides:

• Access to Scientific Documentation: Clinical trial results, white papers, and real-world evidence on IBAL-based therapies.
• Educational and Marketing Materials: Print and digital tools to assist in product onboarding and protocol implementation.
• Regulatory Support: Tools and guidance for navigating country-specific approvals and post-market surveillance.
• Community Building: Networking functions that connect users across the IBAL innovation landscape, enabling an exchange of best practices, case studies, and application methods.

Through this infrastructure, Ionic Alliance helps amplify the brand presence of Ion Gel ZCM-25®, ensuring consistent messaging and training while accelerating clinical adoption in global markets.

Shared Vision: Redefining Wound Care and Infection Control

Ion Gel ZCM-25®, powered by ION-ZCM1, is a Class II COFEPRIS-approved topical gel that combines antimicrobial, anti-inflammatory, and regenerative effects. Designed to combat healthcare-associated infections (HAIs) and accelerate tissue healing, the product’s formulation uses a unique redox-active, low-pH ion delivery system to penetrate tissue effectively while avoiding systemic toxicity.

This collaboration enables:

• Scalable Access to advanced topical treatments across hospitals, clinics, and outpatient settings.
• Expanded Regulatory Pathways: Working in tandem, the partners aim to secure approvals in Latin America, North America, and the European Union.
• Clinical Training and Protocol Development: Supported by case studies and expert guidance, healthcare professionals will be empowered to integrate Ion Gel ZCM-25® into surgical care, wound clinics, and chronic disease management.

By joining forces, Grupo Ion Biotech and Ionic Alliance are creating a global framework for education, deployment, and data sharing—key pillars for any disruptive medical technology.

Toward a Global Standard in Redox-Based Medical Care

As global healthcare systems face growing challenges from antimicrobial resistance, slow-healing wounds, and immunocompromised populations, the need for non-antibiotic, topical immune solutions has never been greater.

Integrating IBAL technology with Ionic Alliance’s digital infrastructure paves the way for a new standard in wound care and infection prevention, one grounded in molecular science, bioavailable ion therapy, and scalable, data-driven implementation.

This partnership is more than a corporate alliance—it’s a strategic step forward in redefining the future of immune system support and regenerative medicine through scientific collaboration and shared global vision.

Learn More

To explore more about Ion Gel ZCM-25®, IBAL technology, and the international efforts behind its success, visit: https://zcm25.com

Together, Grupo Ion Biotech and Ionic Alliance Group are not just advancing a product but shaping the future of healthcare innovation.